J Shahrekord Univ Med Sci. 2023;25(4): 189-193.
doi: 10.34172/jsums.794
  Abstract View: 90
  PDF Download: 107

Original Article

Comparison of inflammatory markers in type 2 diabetic patients treated with empagliflozin, metformin, and sulfonylurea

Pegah Mohaghegh 1* ORCID logo, Mohammad Reza Rezvanfar 2 ORCID logo, Farideh Jalali-Mashayekhi 3 ORCID logo, Zahra Amerei 4 ORCID logo, Mohammad Hosseinzadeh 3 ORCID logo

1 Department of Community Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran
2 Department of Internal Medicine, School of Medicine, Amir-Almomenin Hospital, Arak University of Medical Sciences, Arak, Iran
3 Department of Biochemistry and Genetic, School of Medicine, Arak University of Medical Sciences, Arak, Iran
4 Students Research Committee, Arak University of Medical Sciences, Arak, Iran
*Corresponding Author: Pegah Mohaghegh, Email: pmohaghegh@arakmu.ac.ir


Background and aims: The present study aimed to compare the levels of the inflammatory biomarkers of fibrinogen and high-sensitivity C-reactive protein (hs-CRP) among type 2 diabetic patients treated with empagliflozin and other hypoglycemic drugs.

Methods: This cross-sectional study was performed on 90 patients with type 2 diabetes (≥30 years) receiving empagliflozin, metformin, and sulfonylurea who were referred to the diabetes clinics affiliated with Arak University of Medical Sciences. After obtaining consent to participate in the study, the patients were categorized into the treatment groups of metformin, metformin+empagliflozin, or metformin+sulfonylurea, and their characteristics and hypoglycemic drugs were recorded in the information checklist. The data were analyzed in SPSS 16 statistical software.

Results: The fibrinogen level was minimized in the metformin+empagliflozin group, although the three groups were not significantly different in this regard (P=0.382). Based on the results, the parameter was higher in the individuals with ischemic heart disease, while a lower level was found among those treated with a lipid-lowering agent. In terms of hs-CRP level, no statistically significant difference was observed among the three groups, although the metformin group had a lower level (P=0.522).

Conclusion: The minimum fibrinogen and hs-CRP levels were related to the metformin+empagliflozin and metformin groups, respectively. Further, several factors such as comorbidities and other consumed drugs could affect the concentration of inflammatory factors. Thus, it is suggested that clinical trials should be conducted in this respect.

First Name
Last Name
Email Address
Security code

Abstract View: 91

Your browser does not support the canvas element.

PDF Download: 107

Your browser does not support the canvas element.

Submitted: 18 Sep 2022
Revision: 30 Nov 2022
Accepted: 03 Dec 2022
ePublished: 24 Oct 2023
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)